# Bryan Stuart

> Bryan Stuart is the Chief Executive Officer and a director of Atavistik Bio, a Cambridge, Massachusetts biotechnology company building precision allosteric small molecule therapeutics on its Atavistik Metabolite-Protein Screening (AMPS) platform. He joined in July 2023 after more than two decades leading biopharma companies, including roles as CEO of Fulcrum Therapeutics, Yarra Therapeutics, and Kastle Therapeutics. Under his leadership Atavistik has raised a $120 million Series B in December 2025, later extended to $160 million, to advance its lead programs for hereditary hemorrhagic telangiectasia and myeloproliferative neoplasms toward the clinic.

- **Role:** Chief Executive Officer and Director at Atavistik Bio
- **Organizations:** Atavistik Bio, Fulcrum Therapeutics, Yarra Therapeutics, Kastle Therapeutics, Civitas Therapeutics, EKR Therapeutics, Ovation Pharmaceuticals
- **Nationality:** American
- **Education:** MBA, Kellogg School of Management, Northwestern University, Bachelor's degree, University of Illinois
- **Known for:** Appointed CEO and director of Atavistik Bio in July 2023., Raised a $120 million Series B financing in December 2025 led by Nextech Invest and The Column Group, with new backer Regeneron Ventures., Closed a $40 million Series B extension in March 2026, bringing the round to $160 million.

## Career timeline

- **2023** — Appointed Chief Executive Officer and Director of Atavistik Bio in July.
- **Prior to 2023** — Served as CEO of Fulcrum Therapeutics, having initially joined as Chief Operating Officer.
- **Earlier** — President and CEO of Yarra Therapeutics, a subsidiary of Array BioPharma.
- **Earlier** — CEO of Kastle Therapeutics, focused on rare and severe diseases.
- **Earlier** — Chief Business Officer of Civitas Therapeutics, later acquired by Acorda Therapeutics.
- **Earlier** — Led business and corporate development at EKR Therapeutics, acquired by Chiesi Farmaceutici.
- **Earlier** — Led business development and strategy at Ovation Pharmaceuticals, acquired by Lundbeck A/S.
- **2025** — Led Atavistik Bio's $120 million Series B financing announced in December.
- **2026** — Closed a $40 million Series B extension in March, bringing round proceeds to $160 million; lead HHT program expected to enter the clinic in the first half of the year.

## Achievements

- Appointed CEO and director of Atavistik Bio in July 2023.
- Raised a $120 million Series B financing in December 2025 led by Nextech Invest and The Column Group, with new backer Regeneron Ventures.
- Closed a $40 million Series B extension in March 2026, bringing the round to $160 million.
- Advanced Atavistik's AMPS platform to identify functional allosteric pockets across kinases, enzymes, receptors, transcription factors, protein complexes, and RNA.
- Positioned the company's lead allosteric AKT1-selective inhibitor for hereditary hemorrhagic telangiectasia to enter the clinic in the first half of 2026.
- Held CEO or senior executive roles across at least five biopharma companies, several of which were acquired.

## Latest updates

- **2026-03** — Closed a $40 million Series B extension, bringing total round proceeds to $160 million to advance the pipeline.
- **2025-12** — Raised a $120 million Series B financing led by Nextech Invest and The Column Group with new investor Regeneron Ventures, targeting HHT and MPN programs.

## Links

- Website: https://atavistikbio.com
- LinkedIn: http://www.linkedin.com/in/bryan-stuart-b178ba4

---

Profile page: https://yespress.io/bryan-stuart
Published by YesPress — https://yespress.io
Last updated: 2026-07-22